Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$159.04 -0.81 (-0.51%)
As of: Nov 12, 2026 · 11:28 AM EST

Alnylam Pharmaceuticals (ALNY) Return on Sales [ROS] (2009 - 2026)

Updated

Alnylam Pharmaceuticals' Return on Sales [ROS] came in at 17.93% for Q2 2026, up 20.02 percentage points from -2.09% a year earlier but down 5.09 percentage points from the prior quarter.

Analysis

Alnylam Pharmaceuticals (ALNY) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Alnylam Pharmaceuticals reported Return on Sales [ROS] of 20.81%, up 27.94 percentage points year-over-year; for FY2025, it came in at 13.51%, up 21.37 percentage points from FY2024.

  • Return on Sales [ROS] has increased in each of the last seven years, with a five-year change of +181.60 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Sales [ROS] was -7.87% in FY2024 (+7.57 pp), -15.43% in FY2023 (+60.24 pp), -75.68% in FY2022 (+8.26 pp) and -83.93% in FY2021 (+84.16 pp).
  • The five-year range for quarterly Return on Sales [ROS] is -97.63% (Q3 2022) to 29.46% (Q3 2025).
  • Year-over-year, Return on Sales [ROS] increased in four of the last six quarters, with an average year-over-year change of +8.33 percentage points.
  • The fastest year-over-year change in Return on Sales [ROS] over five years came in Q3 2023 (a gain of 126.12 percentage points), and the weakest in Q3 2024 (a drop of 43.85 percentage points).
  • Business Quant data shows ALNY's Return on Sales [ROS] at 23.02% (Q1 2026), 12.01% (Q4 2025) and 29.46% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Alnylam Pharmaceuticals 20.30 Bn 7.49 Bn 1.10 Bn 23.72%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 23.72%
Jun 30, 2026 17.93%
Mar 31, 2026 23.02%
Dec 31, 2025 12.01%
Sep 30, 2025 29.46%
Jun 30, 2025 -2.09%
Dec 31, 2024 -17.73%
Sep 30, 2024 -15.35%
Jun 30, 2024 7.37%
Mar 31, 2024 -8.79%
Dec 31, 2023 -26.47%
Sep 30, 2023 28.50%
Jun 30, 2023 -72.10%
Mar 31, 2023 -46.92%
Dec 31, 2022 -56.30%
Sep 30, 2022 -97.63%
Jun 30, 2022 -85.26%
Mar 31, 2022 -68.80%
Dec 31, 2021 -75.26%
Sep 30, 2021 -96.83%
API Access

Alnylam Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ALNY&period=max&api_key=YOUR_API_KEY